-
Mashup Score: 0Eplontersen Improves Disease State and QoL in People with Hereditary ATTRv-PN - Practical Neurology - 5 month(s) ago
In the phase 3 clinical trial NEURO-TTRansform (NCT04136184), treatment with eplontersen (AstraZeneca; Cambridge, UK; Ionis Pharmaceuticals, Carslbad,
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1StackPath - 1 year(s) ago
www.evaluate.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation is complete. Reference ID IP Address Date and Time 716654b47b17121f54dbec681e6a6df6 18.223.169.201 11/07/2022 05:22 PM UTC Protected by StackPath
Source: www.evaluate.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 8
New Drug Application filing anticipated based on positive data from interim analysis Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a…
Source: www.astrazeneca.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 2
New Drug Application filing anticipated based on positive data from interim analysis Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks. In the trial, eplontersen reached a…
Source: www.astrazeneca.comCategories: Expert Picks, Latest HeadlinesTweet
-
Mashup Score: 1#Eplontersen granted Orphan Drug Designation in the US for transthyretin #amyloidosis - PHARMA HOUSE - 2 year(s) ago
#Eplontersen has been granted #Orphan Drug Designation (ODD) in the US by the Food and…
Source: PHARMA HOUSECategories: Hem/Oncs, Latest HeadlinesTweet
Subcutaneous #Eplontersen (@AstraZeneca, @ionispharma) was associated with lowered serum TTR concentration, less disability, and better QoL for people with #ATTRv polyneuropathy, according to results published in @JAMA. https://t.co/dYO08OginL